1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
SAMSUNG BIOLOGICS Co., Ltd.

SAMSUNG BIOLOGICS Co., Ltd.

KKRX:207940
1,466,000.00
KRW
+105,000.00
(+7.71%)
39,159.91EPS
32.26P/E
63.89TMarket Cap
Jan 27Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,097.78
2,808.08
7,896.29
10,686.45
12,319.77
16,134.19
26,782.47
36,056.87
66,161.06
79,814.81
75,548.71
67,545.41
98,139.31
Basic EPS, GAAP
-5,561.96
59,072.39
-4,739.12
-2,230.35
5,152.94
4,666.09
5,540.89
9,050.73
17,592.49
18,528.85
23,402.83
26,448.44
42,829.68
Free Cash Flow per Basic Share
-39,729.06
-20,257.62
-6,186.65
-8,164.64
-7,299.72
-3,933.39
1,230.71
769.07
-1,238.39
12,117.3
6,086.2
11,453.8
33,988.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8,945.18
41,497.6
61,051.92
59,467.76
62,144.96
65,120.79
68,774.73
74,641.85
126,232.53
138,119.15
153,211.51
160,962.57
180,839.32
Tangible Book Value per Share
4,275.95
41,283.96
60,841.88
59,183.63
61,846.14
64,794.35
68,425.61
74,160.73
42,475.73
56,177.88
75,018.59
159,662.25
179,178.53
Basic Weighted Avg Shares
17
33
37
43
43
43
43
43
45
46
46
67
46
Sales/Revenue/Turnover
105,149
91,278
294,622
464,629
535,806
701,592
1,164,777
1,568,007
3,001,295
3,694,589
3,497,146
4,556,972
4,546,823
Operating Margin (%)
-113.69
-223.1
-10.33
14.2
10.39
13.08
25.14
34.27
32.77
30.14
37.78
45.41
50.02
Depreciation Expense
26,350
41,628
60,150
69,926
91,451
132,885
143,688
161,789
308,264
489,782
599,101
633,637
498,676
Net Income, GAAP
-95,909
1,920,179
-176,823
-96,972
224,109
202,904
240,975
393,589
798,056
857,691
1,083,316
1,784,352
1,984,312
Effective Tax Rate (%)
- -
23.44
- -
- -
26.03
- -
9.41
29.88
20.91
23.42
24.88
23.8
25.51
Profit Margin (%)
-91.21
2,103.66
-60.02
-20.87
41.83
28.92
20.69
25.1
26.59
23.21
30.98
39.16
43.64
Working Capital
-19,956
-1,718,815
-1,015,120
-1,666,447
867,154
665,756
1,162,046
1,715,881
2,276,115
1,364,127
1,664,929
1,875,449
2,364,999
LT Debt
427,199
681,792
439,363
407,236
486,113
248,808
587,465
1,125,355
1,232,986
377,397
1,020,645
600,124
834,739
Total Equity
630,732
2,774,834
4,082,379
3,976,451
4,155,468
4,354,454
4,598,783
4,991,102
8,984,474
9,830,492
10,904,676
7,451,111
8,361,923
Return on Invested Capital (%)
- -
-6.82
- -
- -
0.86
- -
5.09
6.39
8.59
7.21
8.04
14.69
14.61
Return on Capital (%)
- -
84.73
- -
- -
4.94
- -
4.92
6.92
9.55
7.92
9.19
17.4
17.72
Return on Common Equity (%)
- -
113.86
-5.16
-2.41
5.51
4.77
5.38
8.21
11.42
9.12
10.45
19.44
19.88

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
326,971
346,553
406,535
LT Borrowings
599,012
599,101
599,228
LT Finance Leases
1,112
248,834
235,512
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
77,934,084
69,075,297
63,885,464

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,408,367
4,660,750
5,331,146
Cash, Cash Equivalents & STI
1,485,083
1,652,954
2,212,938
Accounts Receivable, Net
654,728
555,157
573,774
Inventories
2,128,164
2,291,556
2,344,406
Total Current Liabilities
2,532,917
2,740,014
2,966,147
Payables & Accruals
- -
- -
- -
ST Debt
326,971
346,553
406,535
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.66%
15.44%
-31.67%
Free Cash Flow
-147.86%
-255.88%
174.28%
Net Income, GAAP
-21.16%
52.92%
64.71%
Sales/Revenue/Turnover
56.68%
34.82%
30.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
946,903
1,156,904
1,187,075
1,256,439
3,497,146
2025
999,545
1,014,238
1,660,221
308,573
4,556,972
2026
1,257,119
1,320,911
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,874.59
6,869.71
5,713.48
6,898.23
23,402.83
2025
8,112.04
7,008.09
12,409.76
10,954.14
26,448.44
2026
10,148.15
9,314
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Chongbo Rim
Full Time Employees
5,455
Sector
Health technology
Industry
Biotechnology
Address
300, Songdo Bio-daero Inchon IN South Korea 21987
IPO Date
Nov 10, 2016
Website
samsungbiologics.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Samsung Biologics Co., Ltd. (207940.KS) operates as a leading global contract development and manufacturing organization (CDMO) providing end-to-end biologics services from cell line development and process development through clinical and commercial-scale manufacturing, aseptic fill/finish, biosafety testing, and quality assurance; core offerings encompass monoclonal antibodies, bispecific antibodies via the S-DUAL platform, antibody-drug conjugates, mRNA vaccines, and biosimilars support, with proprietary technologies including S-CHOice cell line expression and DEVELOPICK candidate selection, serving biopharmaceutical clients across oncology, immunology, inflammation, and infectious diseases. Founded in 2011 and headquartered in Songdo, Incheon, South Korea, the company maintains cGMP-compliant facilities totaling 784,000 liters capacity across five plants, including the recently operational Plant 5; it conducts operations worldwide with offices in the United States (New Jersey, San Francisco, Boston), Japan (Tokyo), and Europe, targeting top global pharmaceutical firms as clients. In November 2025, Samsung Biologics completed the spin-off of its biosimilars unit Samsung Bioepis into Samsung Epis Holdings to focus exclusively as a pure-play CDMO and address client conflict-of-interest concerns; recent major contracts include a $1.3 billion U.S. manufacturing deal in October 2025, a $1.2 billion Asia-based agreement through 2037, and a $668 million European partnership, alongside partnerships with Pfizer for biosimilars manufacturing, LigaChem Biosciences for ADC pipeline support, and Kurma Partners for development services.

Company News

Company News APIChatGPT

  • prnewswire.com

    Samsung Biologics Reports Second Quarter 2026 Financial Results

  • prnewswire.com

    Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

  • prnewswire.com

    Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth